Skip to main content

FDA OKs Overdose Treatment Device

The U.S. Food and Drug Administration approves a long-awaited handheld device for the treatment of opioid-overdose emergencies.

Written byRina Shaikh-Lesko
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

CENTERS FOR DISEASE CONTROLThe U.S. Food and Drug Administration approved a handheld device from the Richmond, Virginia-based firm Kaléo Pharma to treat opioid overdoses this week (April 3). Called Evzio, the auto-injector—a rectangular device smaller than a deck of cards that delivers a single dose of the drug naloxone—is meant to be used by the suspected overdose victim’s family or caretakers and requires a prescription. FDA fast-tracked Evzio and approved it in just four months from its submission—quickly enough that its manufacturer has not yet set a price.

The U.S. is in the midst of a prescription painkiller epidemic. In 2009, more than 16,000 people died from opioid overdoses in the country. And ongoing efforts to develop a non-addictive pain killer have yet to bear fruit.

The new device works to treat opioid overdoses much in the same way EpiPens are used to treat anaphylactic shock from severe allergic reactions. When opened and activated, the device emits recorded voice instructions to guide users. Regulators warned, however, that the device offers only temporary treatment, and is not meant as a substitute for emergency medical treatment. (The device’s instructions include calling 911.)

“For years, the lack of a lay-friendly delivery system has made it difficult to make naloxone broadly available to the public and to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris
Using TCR Repertoire Sequencing to Advance Immunology Research

Using TCR Repertoire Sequencing to Advance Immunology Research

Miltenyi

Products

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo
Conceptual image of ice and frost.

The VAULT100 PRO: Inside the most advanced Stirling Ultracold ULT freezer ever built.

Stirling Ultracold logo